Literature DB >> 12429716

Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2.

Kenichi Namba1, Nobuyoshi Kitaichi, Tomomi Nishida, Andrew W Taylor.   

Abstract

Recently, we have reported that the cytokines alpha-melanocyte-stimulating hormone (alpha-MSH) and transforming growth factor-beta2 (TGF-beta2) work in synergy to induce the activation of regulatory T (Treg) cells. When we used alpha-MSH and TGF-beta2 to generate ocular autoantigen-specific Treg cells and adoptively transferred them into mice susceptible to experimental autoimmune uveoretinitis (EAU), there was suppression in the incidence and severity of EAU. Specificity to a retinal autoantigen was required for the Treg cells to suppress EAU. When stimulated, these Treg cells produced TGF-beta1, and their production of interferon-gamma, interleukin (IL)-10, and IL-4 was suppressed. Also, the Treg cells are suppressed in their proliferative response. Our results demonstrate that alpha-MSH with TGF-beta2 induce Treg cells that can subdue a tissue-specific autoimmune response. This also promotes the possibility of using these immunomodulating cytokines to purposely induce antigen-specific Treg cells to prevent and suppress autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429716

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  60 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

2.  Human trabecular meshwork cells exhibit several characteristics of, but are distinct from, adipose-derived mesenchymal stem cells.

Authors:  Joshua T Morgan; Joshua A Wood; Naomi J Walker; Vijay Krishna Raghunathan; Dori L Borjesson; Christopher J Murphy; Paul Russell
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-23       Impact factor: 2.671

3.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

4.  Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis.

Authors:  Fauziyya Muhammad; Anna Trivett; Dawei Wang; Darren J Lee
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

Review 5.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

6.  Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-β is critical for immune homeostasis following acute liver injury.

Authors:  Ling Lu; Min Feng; Jia Gu; Zanxian Xia; Hongjun Zhang; Sujun Zheng; Zhongping Duan; Richard Hu; Julie Wang; Wei Shi; Cheng Ji; Yi Shen; Guihua Chen; Song Guo Zheng; Yuan-Ping Han
Journal:  J Mol Cell Biol       Date:  2013-12       Impact factor: 6.216

7.  Murine corneal transplantation: a model to study the most common form of solid organ transplantation.

Authors:  Xiao-Tang Yin; Deena A Tajfirouz; Patrick M Stuart
Journal:  J Vis Exp       Date:  2014-11-17       Impact factor: 1.355

8.  Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice.

Authors:  Darren J Lee; Andrew W Taylor
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

9.  A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis.

Authors:  Joanne Boldison; Tarnjit K Khera; David A Copland; Madeleine L Stimpson; Gemma L Crawford; Andrew D Dick; Lindsay B Nicholson
Journal:  Immunology       Date:  2015-08-11       Impact factor: 7.397

10.  Mechanisms of immune privilege in the anterior segment of the eye: what we learn from corneal transplantation.

Authors:  Junko Hori
Journal:  J Ocul Biol Dis Infor       Date:  2008-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.